We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 582

FDA orders 23andme to stop selling DNA tests

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 12 2013

The U.S. Food and Drug Administration (FDA) issued a warning letter in late November 2013 to 23andMe, Inc., the company that marketed a home "Saliva

Guilty plea entered in cancer-drug smuggling operation

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 21 2014

The owner of an Istanbul, Turkey-based pharmaceutical company has pleaded guilty in a Missouri federal court to charges that he shipped illegal

NIH backs new genetic research center

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 12 2014

The U.S. National Institutes of Health (NIH) has awarded $25 million to the not-for-profit J. Craig Venter Institute (JCVI) to establish and

Grifols acquires 51 percent stake in Araclon Biotech

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 29 2012

Grifols, a Spanish plasma-product manufacturer specializing in the hospitalpharmaceutical sector, has announced that it has acquired 51 percent of the equity of Zaragoza-based Araclon Biotech, a company spun off from the University of Zaragoza in 2004 to develop therapies and diagnostics for Alzheimer’s disease

Oxford Nanopore raises $63.7 million to advance sensing technologies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 17 2013

Oxford Nanopore Technologies Ltd., an Oxford, England-based technology company that develops nanopore-based electronic molecular analysis systems

County pharmaceutical disposal law at issue before Ninth Circuit

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • July 17 2014

The Ninth Circuit Court of Appeals has heard oral argument in an appeal challenging an Alameda County, California law that requires pharmaceutical

Financial group analyzes M&A deals in biotech and medical device industries

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital

Rapid biosimilar growth seen through 2023

  • Shook Hardy & Bacon LLP
  • -
  • Global
  • -
  • May 16 2013

British market-research firm Visiongain has forecast a $2.445-billion global market for biosimilars in 2013, a 20-percent increase over 2012, with

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 12 2014

The U.S. Food and Drug Administration (FDA) issues a final rule amending its "postmarketing safety reporting regulations for human drug and

Supplier sentenced for illegal sales of non-approved drugs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 26 2014

According to the U.S. Department of Justice, a federal court in Virginia has sentenced a U.S. citizen, who owned and operated several companies in